Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Int Forum Allergy Rhinol. 2022 Sep 4;13(2):116–128. doi: 10.1002/alr.23059

Table 1.

Biologics, associated clinical trials, and inclusion criteria

Brand name Generic CRSwNP Clinical Trials Abbreviated study inclusion criteria
Dupixent dupilumab

  1. LIBERTY NP SINUS-24 (Dupi-24)

  2. LIBERTY NP SINUS-52 (Dupi-52)

  1. ≥ 18 years of age

  2. Severe nasal polyposis define by NPS of ≥ 5 (minimum of 2 on each side)

  3. Nasal congestion score of ≥2 (0–3 scale)

  4. At least one other complaint of smell loss or nasal discharge
Xolair omalizumab

  1. POLYP-1 (Oma-1)

  2. POLYP-2 (Oma-2)

  1. 18–75 years of age

  2. Severe nasal polyposis defined by NPS of ≥ 5 (minimum of 2 on each side).

  3. Nasal congestion score of ≥ 2 (0–3 scale)

  4. At least one other complaint of smell loss or nasal discharge

  5. IgE level permitting use (IgE > 30 IU/ml)
Nucala mepolizumab

  1. SYNAPSE (Mepo)

  1. ≥ 18 years of age

  2. Severe nasal polyposis defined by NPS of ≥ 5 (minimum of 2 on each side).

  3. Nasal congestion score of ≥ 5 (on 0–10 VAS scale)

  4. Overall symptom score of 7 (on 0–7 VAS scale)

  5. Prior surgical failure
Endoscopic sinus surgery cohort

  1. ≥ 18 years of age

  2. Severe nasal polyposis defined by Lund-Kennedy score of 4 (2 on each side)

  3. Nasal congestion score of ≥2 (0–3 scale)

  4. At least one other complaint of smell loss or nasal discharge